08:30-09:30registrations hall-2 09:40-09:50 opening … · 08:30-09:30registrations hall-2 day 1...
TRANSCRIPT
08:30-09:30 Registrations
Hall-2
Day 1 August 17, 2015
Group PhotoNetworking & Refreshments 11:35-11:50 @ Foyer
Track 3: Contemporary Challenges of Drug Design, Discovery and DevelopmentTrack 7: Bioavailability, Bioequivalence and Drug Product SelectionTrack 11: Clinical Pharmacology and TherapeuticsTrack 12: Study DesignsSession Chair: Paramjeet Kaur, U.S. Food and Drug Administration, USASession Co-Chair: Aydın Erenmemisoglu, Novagenix Drug R&D Centre, Turkey
Session Introduction
11:50-12:20 Bioequivalence of topical corticosteroids: Design and data analysis challenges with the vasoconstrictor assayKeith Gallicano, Novum Pharmaceutical Research Services, USA
12:20-12:50Prediction of in-vivo permeability, solubility, BCS-classing, food interactions, fraction absorbed and oral bioavailability using new in-silico methods and algorithmsUrban Fagerholm, Prosilico, Sweden
Lunch Break 12:50-13:50 @ Athens
13:50-14:20 Discovery of novel scaffolds for p21-activated kinase 4 inhibitors targeting C- terminalDongmei Zhao, Shenyang Pharmaceutical University, China
Track 1: Emerging Bioavailability and Bioequivalence StudiesTrack 5: Managing BA/BE StudiesTrack 9: Need for Conducting BA/BE StudiesTrack 13: Factors Affecting Bioavailability Session Chair: Paramjeet Kaur, U.S. Food and Drug Administration, USASession Co-Chair: Aydın Erenmemisoglu, Novagenix Drug R&D Centre, Turkey
Session Introduction
14:20-14:50 Optimizing formulation to maximize drug absorption from solution formulationsWenzhan Yang, Astra Zeneca Pharmaceuticals LP, USA
14:50-15:20Design, synthesis and studies of delta and Cox-2 receptor specific analgesic anti-inflammatory activity of some linear and cyclic peptidesSubir Samanta, Birla Institute of Technology, India
Networking & Refreshments15:20-15:35 @ Foyer
15:35-16:05 The Bioequivalence of Citicoline 500mg film tablet Onursal Saglam, Novagenix Biyoanalitik Ilac, Turkey
16:05-1635Possible mistakes and manipulations in bıoequivalency trialsAydın Erenmemisoglu, Novagenix Drug R&D Centre, Turkey
16:35-17:05Mexico and Brazil: Lands for bioequivalence testing and generic product registration IFaB as a choice for your trials in Mexico and BrazilMarlene Teresa Llopiz-Aviles, Harvard University School of Public Health, USA
Panel Discussion
Opening Ceremony09:40-09:50
Keynote Forum09:50-10:00 Introduction10:00-10:35 Paramjeet Kaur U.S. Food and Drug Administration, USA10:35-11:35 Workshop Jim Jingjun Huang Ascendia Pharmaceuticals, USA
Day 2 August 18, 2015
Hall-2Track 2: Bioanalytical MethodologyTrack 4: Regulatory Policies, Procedures and Prerequisites for Clinical ResearchTrack 6: Relevance of Genetics to BA/BE in Drug DevelopmentTrack 8: Advances in Assessment of BioequivalenceTrack 10: Metabolic Pathways and Changes in Nutrient BioavailabilitySession Chair: Subrata Deb, Roosevelt University College of Pharmacy, USASession Co-Chair: Dongmei Zhao, Shenyang Pharmaceutical University, China
Session Introduction
10.00-10.30Effect of formulation development and API characteristics on fast dissolving dosage forms bioequivalence studiesGulay Yelken Demirel, Sanovel Pharmaceuticals, Turkey
10:30-11:00Oral bioavailability and gender-related pharmacokinetics of Celastrol following administration of pure celastrol and its related tablets in ratsWenzheng Ju, Jiangsu Provincial Hospital of Traditional Chinese Medicine, China
11:00-11:30 Preparation and in-vitro evaluation of meloxicam co-ground mixturesAly H Nada, Kuwait University, Kuwait
Networking & Refreshments 11:30-11:45 @ Foyer
11:45-12:15 Impact of glucocorticoids on the bioavailability and metabolism of Abiraterone and Calcitriol Subrata Deb, Roosevelt University College of Pharmacy, USA
12:15-12:45 Comparative analysis, target specicities and plant protection potential of antimicrobial peptides isolated from xenorhabdus speciesAndras Fodor, University of Wisconsin-Madison, USA
Lunch Break 12:45-13:45 @ Athens
13:45-14:15E-BABE- A bioequivalence study of two Nicotine 2mg Lozenge formulations in healthy adult Indian human male smoker subjectsMuneesh Garg, Sitec Labs Pvt Ltd, India
14:15-14:45Eprosartan mesylate cocrystals and their enhanced oral bioavailability studiesJaswanth Santosh Bhandaru, Kakatiya University, India
14:45-15:15In-vitro bioequivalence studies in tablet formulation containing 625mg of Colesevelam hydrochloride
Gulcin Tok, Sanovel Pharmaceuticals, TurkeyNetworking & Refreshments 16:15-16:30 @ Foyer
Panel Discussion
Day 3 August 19, 2015Hall-2
Introduction10:00-11:00 Business to Business Meetings(B2B)
Networking & Refreshments Break 11:00-11:15 @ Foyer11:15-12:30 Academics & Research Meetings
Networking & Lunch Break 12:30-13:30 @ AthensClosing Ceremony
Bookmark your dates
OMICS Group Inc.2360 Corporate Circle, Suite 400Henderson, NV 89074-7722, USA
Ph: +1-888-843-8169Fax: +1-650-618-1417
OMICS International5716 Corsa Ave., Suite 110, Westlake
Los Angeles, CA 91362-7354, USAPh: +1-650-268-9744Fax: +1-650-618-1414
OMICS GroupSEZ Unit, Building No. 20, 9th Floor
APIIC Layout, HITEC CityHyderabad-500081, Telangana, INDIA
Ph: 040-40131823, [email protected]
Toll freeUSA & Canada: +1-800-216-6499
Australia: +1-800-651-097Europe: 0805-080048
Global Pharma SummitAugust 01-03, 2016 Toronto, Canada
7th Annual
Website: american.pharmaceuticalconferences.come-mail: [email protected]; [email protected]
European Pharma CongressJune 13-15, 2016 Berlin, Germany
4th Annual
Website: europe.pharmaceuticalconferences.come-mail: [email protected]; [email protected]
Bioavailability & Bioequivalence:BA/BE Studies Summit
August 29-31, 2016 SanFransisco, USA
7th World Congress on
Website: bioavailability-bioequivalence.pharmaceuticalconferences.come-mail: [email protected]; [email protected]